Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487691 · ClinicalTrials.gov registry record · NA
Nebulized PL for Post-COVID-19 Syndrome
A NA study, sponsored by Regenexx.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04487691: Clinical Trial NA study, sponsored by Regenexx.
NCT04487691 is a NA study that was terminated before completion, run by Regenexx. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04487691, a NA study, was terminated before completion, sponsored by Regenexx.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
To evaluate and compare nebulized platelet lysate to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.
Primary Outcome
Changes in pre and post treatment spirometry measures
Interventions
- BIOLOGICAL Nebulized Platelet Lysate
- OTHER Nebulized Sterile Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2021-06-15 |
| Phase | NA |
Why NCT04487691 stopped before completion
NCT04487691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Nebulized Platelet Lysate is the first listed.
NCT04487691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04487691 about?
NCT04487691 is a clinical study titled "Nebulized PL for Post-COVID-19 Syndrome". To evaluate and compare nebulized platelet lysate to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.
What is the current status of trial NCT04487691?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2020-12-08. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT04487691?
The interventions under investigation include: Nebulized Platelet Lysate (BIOLOGICAL), Nebulized Sterile Saline (OTHER).
Who is sponsoring clinical trial NCT04487691?
This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04487691's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI